Screener
Immix Biopharma, Inc. IMMX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable and accrued expenses | $10,414,266 | $9,971,207 |
| Operating lease liability - current | 125,392 | 139,339 |
| Total current liabilities | 10,539,658 | 10,110,546 |
| Operating lease liability – long term | 912,343 | 933,625 |
| Total liabilities | 11,452,001 | 11,044,171 |
| Commitments and contingencies | - | - |
| Stockholders’ equity: |
Document
FAQ
- What is Immix Biopharma, Inc.'s total current liabilities?
- Immix Biopharma, Inc. (IMMX) reported total current liabilities of $10.54M in Q1 2026.
- How has Immix Biopharma, Inc.'s total current liabilities changed year-over-year?
- Immix Biopharma, Inc.'s total current liabilities increased by 13.2% year-over-year, from $9.31M to $10.54M.
- What is the long-term trend for Immix Biopharma, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s total current liabilities has grown at a 13.9% compound annual growth rate (CAGR), from $5.27M to $10.11M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Immix Biopharma, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude